Medipal Holdings Corp distributes pharmaceuticals and health and beauty products to medical institutions and retailers... Show more
The 10-day moving average for MAHLY crossed bullishly above the 50-day moving average on July 17, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 52 cases where MAHLY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 04, 2025. You may want to consider a long position or call options on MAHLY as a result. In of 52 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MAHLY just turned positive on August 05, 2025. Looking at past instances where MAHLY's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
MAHLY moved above its 50-day moving average on July 16, 2025 date and that indicates a change from a downward trend to an upward trend.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
MAHLY broke above its upper Bollinger Band on July 16, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MAHLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MAHLY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.917) is normal, around the industry mean (7.892). P/E Ratio (13.477) is within average values for comparable stocks, (29.460). MAHLY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (4.521). Dividend Yield (0.020) settles around the average of (0.032) among similar stocks. P/S Ratio (0.156) is also within normal values, averaging (35.215).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalDistributors